Swallowable Device Can Test for DNA Markers of Barrett's

This article originally appeared here.
Share this content:
Swallowable Device Can Test for DNA Markers of Barrett's
Swallowable Device Can Test for DNA Markers of Barrett's

TUESDAY, Jan. 23, 2018 (HealthDay News) -- A swallowable balloon device has been developed to obtain samples from the lower esophagus -- samples which then undergo assay of combined CCNA1 and VIM DNA methylation to detect Barrett's esophagus metaplasia, according to a study published online Jan. 17 in Science Translational Medicine.

Helen R. Moinova, Ph.D., from the Case Western Reserve University in Cleveland, and colleagues developed a well-tolerated swallowable, encapsulated balloon device that was able to selectively sample the distal esophagus within five minutes, and was further engineered to progress toward non-endoscopic esophageal screening. The authors had ascertained regions targeted for recurrent aberrant cytosine methylation in BE with genome-wide screening, identifying high-frequency methylation within the CCNA1 locus. CCNA1 DNA methylation was assessed as a BE biomarker in cytology brushings of the distal esophagus from 173 individuals with or without BE.

The researchers found that for discriminating BE-related metaplasia and neoplasia cases versus normal individuals, CCNA1 DNA methylation had an area under the curve of 0.95, which was identical to that of VIM DNA methylation. The resulting two biomarker panel (combining CCNA1 and VIM DNA methylation) had sensitivity and specificity of 95 and 91 percent, respectively. In an independent validation cohort of 149 individuals, these results were replicated. Tests of CCNA1 plus VIM DNA methylation detected BE metaplasia with 90.3 and 91.7 percent sensitivity and specificity, respectively, in balloon samples from 86 individuals.

"Combining the balloon sampling device with molecular assays of CCNA1 plus VIM DNA methylation enables an efficient, well-tolerated, sensitive, and specific method of screening at-risk populations for BE," the authors write.

Several authors disclosed having been awarded patents and having pending patents. Several authors disclosed ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »